Palbociclib Plus Fulvestrant Maintains Long-Term Overall Survival Benefit in HR+/HER2- Advanced Breast Cancer

Oncologist. 2021 Jun 21. doi: 10.1002/onco.13864. Online ahead of print.NO ABSTRACTPMID:34152059 | DOI:10.1002/onco.13864
Source: The Oncologist - Category: Cancer & Oncology Source Type: research